A patient on duloxetine 90 mg daily for depression has worsening symptoms; what medication adjustments or additions should be made?

Switch to a Different Antidepressant or Add Augmentation Therapy

For a patient on duloxetine 90 mg daily with worsening depression, you should either switch to a different antidepressant class or add augmentation therapy, as the patient has failed an adequate trial at a dose above the standard therapeutic range.

Rationale for This Recommendation

Your patient is already on 90 mg daily of duloxetine, which exceeds the FDA-approved maximum dose of 60 mg twice daily (120 mg/day total) for depression 1. The standard therapeutic dose is 60 mg once daily, with the maximum being 120 mg/day in divided doses 1. Since depression is worsening rather than improving, this represents treatment failure at an adequate—indeed, supratherapeutic—dose.

Treatment Options

Option 1: Switch to a Different Antidepressant Class (Preferred Initial Strategy)

Switch to an alternative first-line antidepressant from a different class:

• SSRIs (escitalopram, sertraline, fluoxetine): Different mechanism may provide better response
• Bupropion: Particularly if patient has low energy, hypersomnia, or sexual dysfunction concerns
• Mirtazapine: Especially if insomnia or poor appetite are prominent
• Tricyclic antidepressants (nortriptyline, desipramine): If no cardiac contraindications and age <40 years without ECG abnormalities

The 2023 ACP guidelines indicate that various switch strategies (switching to bupropion SR, escitalopram, sertraline, or venlafaxine) show similar efficacy 2. The 2008 ACP guidelines emphasize that insufficient evidence exists to prefer one agent over another as second-line therapy, but switching is appropriate when there is inadequate response after 6-8 weeks 3.

Option 2: Augmentation Strategy

Add one of the following to continue duloxetine:

• Bupropion SR (150-450 mg/day): Well-studied augmentation agent with complementary mechanism 4, 2
• Aripiprazole (2-15 mg/day): FDA-approved for augmentation in treatment-resistant depression
• Cognitive Behavioral Therapy (CBT): Evidence shows similar efficacy to medication augmentation 2

The STAR*D trial demonstrated similar efficacy between augmenting with bupropion SR, buspirone, or cognitive therapy, though bupropion had lower discontinuation rates due to adverse events compared to buspirone 2.

Option 3: Switch vs. Augmentation—No Clear Winner

Two trials with 1,231 participants found no differences in efficacy or safety between switching versus augmenting strategies 2. However, in clinical practice with worsening symptoms, switching is often preferred initially to avoid polypharmacy and simplify the regimen, especially since the patient is already at a high duloxetine dose.

Critical Monitoring Points

Before Making Changes:

1. Verify medication adherence and actual dosing schedule
2. Screen for bipolar disorder risk factors (family history, prior manic/hypomanic episodes) before switching, as antidepressant monotherapy can precipitate mania 1
3. Assess for suicidal ideation—worsening depression increases suicide risk, particularly in the first 1-2 months after treatment changes 1
4. Check for substance use, particularly alcohol, which can worsen depression and interact with duloxetine 1

When Discontinuing Duloxetine:

Taper gradually to avoid discontinuation syndrome 1:

• Common withdrawal symptoms: dizziness, headache, nausea, paresthesias, irritability, insomnia
• Reduce dose by 30 mg every 1-2 weeks rather than abrupt cessation
• If switching to an MAOI, allow 5 days washout after stopping duloxetine 1

Common Pitfalls to Avoid

1. Don't increase duloxetine beyond 120 mg/day—no evidence of additional benefit and increased adverse effects 5, 6
2. Don't assume dose escalation will work—one study showed no advantage of increasing from 60 mg to 120 mg in non-responders 6
3. Don't delay switching—if no adequate response after 6-8 weeks at therapeutic doses, modification is indicated 3
4. Don't overlook comorbid anxiety—if prominent, consider SNRIs like venlafaxine or SSRIs rather than bupropion alone 4

Timeline Expectations

• Reassess within 1-2 weeks after any medication change for worsening symptoms or suicidality 3
• Expect 6-8 weeks for full therapeutic effect of new medication 3
• If no response after 6-8 weeks of adequate trial with second agent, consider referral to psychiatry or third-line options 3